Formosa Laboratories Inc Net Assets
Formosa Laboratories Inc net assets. Based on the latest financial reports, Formosa Laboratories Inc (4746) has net assets worth NT$8.68 Billion TWD (≈ $273.60 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$13.70 Billion ≈ $431.57 Million USD) and total liabilities (NT$5.01 Billion ≈ $157.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 4746 net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$8.68 Billion |
| % of Total Assets | 63.4% |
| Annual Growth Rate | 12.42% |
| 5-Year Change | 14.05% |
| 10-Year Change | 111.28% |
| Growth Volatility | 16.53 |
Net Assets of Formosa Laboratories Inc (2009–2025)
Net assets of Formosa Laboratories Inc from 2009 to 2025. This chart illustrates how Formosa Laboratories Inc's net assets have evolved over time, based on quarterly financial data. Also explore 4746 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Net Assets for Formosa Laboratories Inc (2009–2025)
The table below shows the annual net assets of Formosa Laboratories Inc from 2009 to 2025. For live market cap and overall valuation, see 4746 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$8.67 Billion ≈ $273.16 Million |
+0.27% |
| 2024-12-31 | NT$8.65 Billion ≈ $272.42 Million |
+5.32% |
| 2023-12-31 | NT$8.21 Billion ≈ $258.67 Million |
+5.31% |
| 2022-12-31 | NT$7.80 Billion ≈ $245.63 Million |
+2.55% |
| 2021-12-31 | NT$7.60 Billion ≈ $239.51 Million |
+43.82% |
| 2020-12-31 | NT$5.29 Billion ≈ $166.53 Million |
+18.59% |
| 2019-12-31 | NT$4.46 Billion ≈ $140.43 Million |
-2.21% |
| 2018-12-31 | NT$4.56 Billion ≈ $143.60 Million |
+11.14% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.20 Million |
-0.07% |
| 2016-12-31 | NT$4.10 Billion ≈ $129.29 Million |
+18.53% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.08 Million |
+14.07% |
| 2014-12-31 | NT$3.04 Billion ≈ $95.63 Million |
+20.65% |
| 2013-12-31 | NT$2.52 Billion ≈ $79.26 Million |
+50.25% |
| 2012-12-31 | NT$1.67 Billion ≈ $52.75 Million |
-10.93% |
| 2011-12-31 | NT$1.88 Billion ≈ $59.23 Million |
+34.92% |
| 2010-12-31 | NT$1.39 Billion ≈ $43.90 Million |
+4.57% |
| 2009-12-31 | NT$1.33 Billion ≈ $41.98 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Formosa Laboratories Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 853.3% over the analyzed period, indicating profitable operations and earnings retention.
Formosa Laboratories Inc Net Assets Breakdown (December 2025)
Formosa Laboratories Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$3.17 Billion | 40.85% |
| Common Stock | NT$1.20 Billion | 15.50% |
| Other Comprehensive Income | NT$505.61 Million | 6.52% |
| Other Components | NT$2.88 Billion | 37.13% |
| Total Equity | NT$7.76 Billion | 100.00% |
Formosa Laboratories Inc Competitors by Market Cap
The table below lists competitors of Formosa Laboratories Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thrace Plastics Holding and Commercial S.A
AT:PLAT
|
$174.92 Million |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
$174.97 Million |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
$175.00 Million |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
$175.01 Million |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
$174.84 Million |
|
Patriot Acquisition Corp.
NASDAQ:PTAC
|
$174.82 Million |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
$174.82 Million |
|
CMC Corp
VN:CMG
|
$174.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Formosa Laboratories Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,684,075,000 to 7,757,183,000, a change of 73,108,000 (1.0%).
- Net income of 441,107,000 contributed positively to equity growth.
- Dividend payments of 360,767,000 reduced retained earnings.
- Other comprehensive income increased equity by 25,718,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$441.11 Million | +5.69% |
| Dividends Paid | NT$360.77 Million | -4.65% |
| Other Comprehensive Income | NT$25.72 Million | +0.33% |
| Other Changes | NT$-32.95 Million | -0.42% |
| Total Change | NT$- | 0.95% |
Book Value vs Market Value Analysis
This analysis compares Formosa Laboratories Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.25x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$36.96 | NT$46.15 | x |
| 2010-12-31 | NT$22.33 | NT$46.15 | x |
| 2011-12-31 | NT$27.91 | NT$46.15 | x |
| 2012-12-31 | NT$24.89 | NT$46.15 | x |
| 2013-12-31 | NT$35.14 | NT$46.15 | x |
| 2014-12-31 | NT$33.59 | NT$46.15 | x |
| 2015-12-31 | NT$36.60 | NT$46.15 | x |
| 2016-12-31 | NT$43.58 | NT$46.15 | x |
| 2017-12-31 | NT$42.27 | NT$46.15 | x |
| 2018-12-31 | NT$43.13 | NT$46.15 | x |
| 2019-12-31 | NT$43.57 | NT$46.15 | x |
| 2020-12-31 | NT$44.04 | NT$46.15 | x |
| 2021-12-31 | NT$60.87 | NT$46.15 | x |
| 2022-12-31 | NT$62.21 | NT$46.15 | x |
| 2023-12-31 | NT$62.83 | NT$46.15 | x |
| 2024-12-31 | NT$63.90 | NT$46.15 | x |
| 2025-12-31 | NT$71.89 | NT$46.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Formosa Laboratories Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.69%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.09%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.78x
- Recent ROE (5.69%) is below the historical average (7.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 16.96% | 11.90% | 1.12x | 1.27x | NT$92.68 Million |
| 2010 | 17.70% | 9.84% | 1.06x | 1.70x | NT$107.29 Million |
| 2011 | 12.29% | 8.80% | 0.84x | 1.66x | NT$43.08 Million |
| 2012 | 0.30% | 0.20% | 0.63x | 2.41x | NT$-162.43 Million |
| 2013 | -2.76% | -2.81% | 0.50x | 1.98x | NT$-320.97 Million |
| 2014 | 8.65% | 10.52% | 0.44x | 1.87x | NT$-41.03 Million |
| 2015 | 8.16% | 10.87% | 0.40x | 1.86x | NT$-63.83 Million |
| 2016 | 11.78% | 15.16% | 0.47x | 1.64x | NT$73.08 Million |
| 2017 | 5.94% | 9.40% | 0.35x | 1.80x | NT$-163.29 Million |
| 2018 | 4.01% | 6.58% | 0.31x | 1.98x | NT$-263.91 Million |
| 2019 | -0.94% | -1.49% | 0.29x | 2.20x | NT$-477.24 Million |
| 2020 | 7.69% | 13.01% | 0.30x | 1.98x | NT$-120.47 Million |
| 2021 | 16.89% | 39.75% | 0.26x | 1.62x | NT$509.57 Million |
| 2022 | 2.88% | 5.76% | 0.30x | 1.70x | NT$-535.25 Million |
| 2023 | 1.67% | 2.90% | 0.32x | 1.80x | NT$-630.85 Million |
| 2024 | 2.05% | 3.32% | 0.34x | 1.81x | NT$-611.14 Million |
| 2025 | 5.69% | 9.09% | 0.35x | 1.78x | NT$-334.61 Million |
Industry Comparison
This section compares Formosa Laboratories Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,980,425,400
- Average return on equity (ROE) among peers: 11.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Formosa Laboratories Inc (4746) | NT$8.68 Billion | 16.96% | 0.58x | $174.85 Million |
| Grape King Bio Ltd (1707) | $2.74 Billion | 22.57% | 0.41x | $397.64 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $2.58 Billion | 10.38% | 0.28x | $320.90 Million |
| Maywufa Co Ltd (1731) | $2.04 Billion | 8.30% | 0.39x | $88.36 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.64 Billion | 13.21% | 0.19x | $484.55 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $17.33 Billion | 23.69% | 0.90x | $1.45 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $36.38 Million |
| LIWANLI Innovation Co Ltd (3054) | $684.56 Million | 0.00% | 0.08x | $139.75 Million |
| YungShin Global Holding Corp (3705) | $7.70 Billion | 10.89% | 0.54x | $495.96 Million |
| TTY Biopharm Co Ltd (4105) | $6.39 Billion | 22.86% | 0.42x | $631.41 Million |
| Phytohealth Corp (4108) | $294.31 Million | 0.00% | 0.04x | $74.15 Million |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more